MCID: CRB088
MIFTS: 39

Cerebral Atrophy

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Cerebral Atrophy

MalaCards integrated aliases for Cerebral Atrophy:

Name: Cerebral Atrophy 55 30 6 74

Classifications:



External Ids:

UMLS 74 C0235946

Summaries for Cerebral Atrophy

NINDS : 55 Cerebral atrophy is a common feature of many of the diseases that affect the brain. Atrophy of any tissue means loss of cells. In brain tissue, atrophy describes a loss of neurons and the connections between them. Atrophy can be generalized, which means that all of the brain has shrunk; or it can be focal, affecting only a limited area of the brain and resulting in a decrease of the functions that area of the brain controls. If the cerebral hemispheres (the two lobes of the brain that form the cerebrum) are affected, conscious thought and voluntary processes may be impaired. Associated Diseases/Disorders: The pattern and rate of progression of cerebral atrophy depends on the disease involved. Diseases that cause cerebral atrophy include: stroke and traumatic brain injury Alzheimer’s disease, Pick’s disease, and fronto-temporal dementia cerebral palsy, in which lesions (damaged areas) may impair motor coordination Huntington’s disease, and other hereditary diseases that are associated with genetic mutations leukodystrophies, such as Krabbe disease, which destroy the myelin sheath that protects axons mitochondrial encephalomyopathies, such as Kearns-Sayre syndrome, which interfere with the basic functions of neurons multiple sclerosis, which causes inflammation, myelin damage, and lesions in cerebral tissue infectious diseases, such as encephalitis, neurosyphilis, and AIDS, in which an infectious agent or the inflammatory reaction to it destroys neurons and their axons Symptoms of cerebral atrophy: Many diseases that cause cerebral atrophy are associated with dementia, seizures, and a group of language disorders called the aphasias.  Dementia is characterized by a progressive impairment of memory and intellectual function that is severe enough to interfere with social and work skills. Memory, orientation, abstraction, ability to learn, visual-spatial perception, and higher executive functions such as planning, organizing, and sequencing may also be impaired. Seizures can take different forms, appearing as disorientation, repetitive movements, loss of consciousness, or convulsions. Aphasias are a group of disorders characterized by disturbances in speaking and understanding language. Receptive aphasia causes impaired comprehension. Expressive aphasia is reflected in odd choices of words, the use of partial phrases, disjointed clauses, and incomplete sentences.

MalaCards based summary : Cerebral Atrophy is related to ceroid lipofuscinosis, neuronal, 1 and ceroid lipofuscinosis, neuronal, 10, and has symptoms including headache An important gene associated with Cerebral Atrophy is VPS53 (VPS53 Subunit Of GARP Complex), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs Aspirin and Interferon beta-1b have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and testes, and related phenotypes are mortality/aging and nervous system

Wikipedia : 77 Cerebral atrophy is a common feature of many of the diseases that affect the brain.Atrophy of any tissue... more...

Related Diseases for Cerebral Atrophy

Diseases in the Cerebral Atrophy family:

Autosomal Recessive Cerebral Atrophy

Diseases related to Cerebral Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Related Disease Score Top Affiliating Genes
1 ceroid lipofuscinosis, neuronal, 1 31.2 CLN6 DNAJC5
2 ceroid lipofuscinosis, neuronal, 10 31.1 CLN6 DNAJC5
3 ceroid lipofuscinosis, neuronal, 7 31.1 CLN6 DNAJC5
4 ceroid lipofuscinosis, neuronal, 2 30.9 CLN6 DNAJC5
5 keratosis follicularis, dwarfism, and cerebral atrophy 12.5
6 autosomal recessive cerebral atrophy 12.1
7 pontocerebellar hypoplasia, type 2e 11.9
8 prieto x-linked mental retardation syndrome 11.9
9 pontocerebellar hypoplasia, type 2d 11.4
10 incontinentia pigmenti 11.3
11 pontocerebellar hypoplasia, type 2a 11.2
12 asparagine synthetase deficiency 11.2
13 aicardi-goutieres syndrome 1 11.1
14 aicardi-goutieres syndrome 3 11.1
15 neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant 11.1
16 epileptic encephalopathy, early infantile, 17 11.1
17 aicardi-goutieres syndrome 7 11.1
18 neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination 11.1
19 neurodevelopmental disorder with involuntary movements 11.1
20 encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities 11.1
21 ceroid lipofuscinosis, neuronal, 4b, autosomal dominant 10.9
22 ceroid lipofuscinosis, neuronal, 3 10.9
23 ceroid lipofuscinosis, neuronal, 4a, autosomal recessive 10.9
24 galloway-mowat syndrome 1 10.9
25 ceroid lipofuscinosis, neuronal, 5 10.9
26 oculopalatocerebral syndrome 10.9
27 peho syndrome 10.9
28 congenital disorder of glycosylation, type iim 10.9
29 mohr-tranebjaerg syndrome 10.9
30 ceroid lipofuscinosis, neuronal, 8 10.9
31 ceroid lipofuscinosis, neuronal, 6 10.9
32 encephalopathy, familial, with neuroserpin inclusion bodies 10.9
33 aicardi-goutieres syndrome 2 10.9
34 aicardi-goutieres syndrome 4 10.9
35 aicardi-goutieres syndrome 5 10.9
36 aicardi-goutieres syndrome 6 10.9
37 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.9
38 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.9
39 shashi-pena syndrome 10.9
40 3-methylglutaconic aciduria, type viii 10.9
41 neurodevelopmental disorder with hypotonia, seizures, and absent language 10.9
42 epileptic encephalopathy, early infantile, 51 10.9
43 leukodystrophy, progressive, early childhood-onset 10.9
44 aicardi-goutieres syndrome 10.9
45 cerebellum agenesis hydrocephaly 10.9
46 dementia 10.4
47 multiple sclerosis 10.3
48 alzheimer disease 10.3
49 hydrocephalus 10.3
50 aging 10.2

Graphical network of the top 20 diseases related to Cerebral Atrophy:



Diseases related to Cerebral Atrophy

Symptoms & Phenotypes for Cerebral Atrophy

UMLS symptoms related to Cerebral Atrophy:


headache

MGI Mouse Phenotypes related to Cerebral Atrophy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.43 CLN6 DNAJC3 DNAJC5 GNAO1 RNASEH2B VPS53
2 nervous system MP:0003631 9.02 CLN6 DNAJC3 DNAJC5 GNAO1 RNASEH2B

Drugs & Therapeutics for Cerebral Atrophy

Drugs for Cerebral Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Interferon beta-1b Approved Phase 4,Phase 2 145155-23-3
3
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2 145258-61-3 6438354
4
Memantine Approved, Investigational Phase 4 19982-08-2 4054
5
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
leucovorin Approved Phase 4 58-05-9 143 6006
11
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
12
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
13
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
14
Galantamine Approved Phase 4,Phase 3 357-70-0 9651
15
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
16
Rivaroxaban Approved Phase 4 366789-02-8
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
19
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
23 Fibrinolytic Agents Phase 4
24 Cyclooxygenase Inhibitors Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
26 Antipyretics Phase 4
27 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
28 Platelet Aggregation Inhibitors Phase 4,Phase 1,Phase 2
29 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
31 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Interferon-beta Phase 4,Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
36 interferons Phase 4,Phase 3,Phase 2,Phase 1
37 Hormones Phase 4,Phase 2,Not Applicable
38 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Excitatory Amino Acids Phase 4,Phase 2
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
43 Excitatory Amino Acid Antagonists Phase 4,Phase 2
44 Dopamine Agents Phase 4
45 Fingolimod Hydrochloride Phase 4,Phase 1,Phase 2
46 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Prednisolone acetate Phase 4
48 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Antineoplastic Agents, Hormonal Phase 4,Phase 2
50 Hormone Antagonists Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 179)
# Name Status NCT ID Phase Drugs
1 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Unknown status NCT01650792 Phase 4 Aspirin
2 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4 Memantine;Placebo
3 Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease) Completed NCT00334906 Phase 4 memantine HCl
4 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
5 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4 Interferon-beta-1a (Avonex) plus methylprednisolone
6 AVONEX® Combination Trial - "ACT" Completed NCT00112034 Phase 4 Methotrexate;IV methylprednisolone
7 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4 Cystagon
8 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4 Interferon-beta-1a;methylprednisolone
9 The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease Completed NCT01921972 Phase 4 Galantamine CR;Memantine;Placebo
10 Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis Recruiting NCT03345940 Phase 4 Fingolimod;Dimethyl Fumarate
11 Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Recruiting NCT02168829 Phase 4 Rivaroxaban;Acetylsalicylic acid
12 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke Recruiting NCT02684825 Phase 4
13 Effect of Fingolimod on Neurodegeneration Terminated NCT02575365 Phase 4 0,5 mg Fingolimod
14 Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate Terminated NCT00203047 Phase 4 Glatiramer Acetate;Placebo;Prednisone
15 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3 Sunphenon EGCG;Placebo
16 IMaging Della PLAcca Carotidea Completed NCT03333330 Phase 3 Visipaque 320 and SonoVue
17 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
18 Magnetic Stimulation Therapy for Treating Vascular Depression Completed NCT00044798 Phase 3 Citalopram
19 A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment Completed NCT00236574 Phase 3 Galantamine hydrobromide
20 Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Completed NCT01110720 Phase 2, Phase 3 Davunetide;Placebo
21 A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo Completed NCT01067521 Phase 3 Glatiramer acetate (GA);Placebo
22 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed NCT02008721 Phase 3 EGCG as putative neuroprotective agent;Placebo
23 Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline Completed NCT00878631 Phase 2, Phase 3 hypertonic saline mixed with dextran;Normal Saline
24 The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT01707992 Phase 3 Laquinimod;Placebo
25 Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome Completed NCT00666224 Phase 3 Glatiramer Acetate (DB);Placebo;Glatiramer Acetate (OL)
26 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
27 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
28 Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease Completed NCT00951834 Phase 2, Phase 3 Epigallocatechin-Gallate;Placebo
29 Omega-3 Fatty Acid Treatment in Multiple Sclerosis Completed NCT00360906 Phase 2, Phase 3 Triomar™ (omega-3 fatty acids)
30 An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab Completed NCT00930553 Phase 3
31 Multiple Sclerosis-Simvastatin Trial 2 Recruiting NCT03387670 Phase 3 Simvastatin;Placebo
32 Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome Recruiting NCT03122652 Phase 3 Teriflunomide 14 MG Oral Tablet [Aubagio];Placebo Oral Tablet
33 RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS Recruiting NCT03477500 Phase 3 Cyclophosphamide and ATG;Alemtuzumab
34 A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Recruiting NCT03131453 Phase 2, Phase 3 CNP520 50mg;CNP520 15mg
35 National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis Active, not recruiting NCT02937285 Phase 3 Interferon beta 1a;Mitoxantrone
36 Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Active, not recruiting NCT02201108 Phase 3 Teriflunomide;Placebo
37 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) Active, not recruiting NCT00835770 Phase 3 dimethyl fumarate;Placebo
38 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
39 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
40 An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Terminated NCT01578785 Phase 3 Glatiramer Acetate;Placebo
41 Phase 3 IGIV, 10% in Alzheimer´s Disease Terminated NCT01524887 Phase 3
42 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
43 Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients Terminated NCT00676143 Phase 3 bapineuzumab;placebo
44 Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients Terminated NCT00667810 Phase 3 bapineuzumab;bapineuzumab;placebo
45 Long-Term Study of IGIV, 10% in Alzheimer´s Disease Terminated NCT01736579 Phase 3 Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
46 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
47 A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis Unknown status NCT00217295 Phase 2 Avonex and Topamax
48 Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) Unknown status NCT03022968 Phase 2 [18F]T807 PET
49 The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis Unknown status NCT00917839 Phase 2 lamotrigine
50 Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination Unknown status NCT01627938 Phase 2 Dexrazoxane (DRZ) plus Mitoxantrone (MX);Placebo plus Mitoxantrone (MX)

Search NIH Clinical Center for Cerebral Atrophy

Genetic Tests for Cerebral Atrophy

Genetic tests related to Cerebral Atrophy:

# Genetic test Affiliating Genes
1 Cerebral Atrophy 30

Anatomical Context for Cerebral Atrophy

MalaCards organs/tissues related to Cerebral Atrophy:

42
Brain, Bone, Testes, Kidney, Spinal Cord, T Cells, Retina

Publications for Cerebral Atrophy

Articles related to Cerebral Atrophy:

(show top 50) (show all 423)
# Title Authors Year
1
Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. ( 30846243 )
2019
2
The Shrinking Brain: Cerebral Atrophy Following Traumatic Brain Injury. ( 30341741 )
2018
3
Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities. ( 29314393 )
2018
4
Homocysteine and Cerebral Atrophy: The Epidemiology of Dementia in Singapore Study. ( 29480177 )
2018
5
Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy. ( 29691655 )
2018
6
Caregiver Burden in Semantic Dementia with Right- and Left-Sided Predominant Cerebral Atrophy and in Behavioral-Variant Frontotemporal Dementia. ( 29706989 )
2018
7
Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study. ( 29960604 )
2018
8
Unilateral Cerebral Atrophy: Severe Neuroimaging Feature of Incontinentia Pigmenti without Acute Encephalopathic State. ( 30090155 )
2018
9
Progressive cerebello-cerebral atrophy and progressive encephalopathy with edema, hypsarrhythmia and optic atrophy may be allelic syndromes. ( 30100179 )
2018
10
Cerebral Atrophy and Leukoencephalopathy in a Young Man Presenting With Encephalitic Episodes. ( 30167633 )
2018
11
Visual rating assessment of cerebral atrophy and its relationship with cognitive function in chronic obstructive pulmonary disease. ( 30555707 )
2018
12
A novel TRAPPC11 mutation in two Turkish families associated with cerebral atrophy, global retardation, scoliosis, achalasia and alacrima. ( 27707803 )
2017
13
Cockayne syndrome with intracranial calcification, hypomyelination, and cerebral atrophy. ( 28149095 )
2017
14
Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma. ( 28182114 )
2017
15
Blood Pressure Control in Aging Predicts Cerebral Atrophy Related to Small-Vessel White Matter Lesions. ( 28555103 )
2017
16
Association of White Matter Lesions, Cerebral Atrophy, Intracranial Extravascular Calcifications, and Ventricular-Communicating Hydrocephalus with Delirium Among Veterans. ( 28575905 )
2017
17
White matter lesions characterise brain involvement in moderate to severe chronic obstructive pulmonary disease, but cerebral atrophy does not. ( 28629404 )
2017
18
Interferon-γ Is Associated with Cerebral Atrophy in Systemic Lupus Erythematosus. ( 28848179 )
2017
19
Pontine and cerebral atrophy in Lennox-Gastaut syndrome. ( 26808205 )
2016
20
Reversible Cerebral Atrophy in Infantile Tremor Syndrome. ( 27395831 )
2016
21
On a remarkable syndrome of cerebral atrophy associated with hyperammonaemia in childhood. ( 27577062 )
2016
22
Does Side of Onset Influence the Pattern of Cerebral Atrophy in Parkinson's Disease? ( 27672378 )
2016
23
Impaired fasting blood glucose is associated to cognitive impairment and cerebral atrophy in middle-aged non-human primates. ( 28039490 )
2016
24
Retinal neurodegeneration on optical coherence tomography and cerebral atrophy. ( 25451722 )
2015
25
An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. ( 25516199 )
2015
26
Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors. ( 25523616 )
2015
27
Evolution of a symptomatic diffuse developmental venous anomaly with progressive cerebral atrophy in an atypical case of Sturge-Weber syndrome. ( 25547041 )
2015
28
Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. ( 25990306 )
2015
29
Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. ( 26239178 )
2015
30
Progressive cerebral atrophy in neuromyelitis optica. ( 26359279 )
2015
31
Parry-Romberg syndrome associated with contralateral cerebral atrophy. ( 26771367 )
2015
32
Long-Term Migration of a Deep Brain Stimulation (DBS) Lead in the Third Ventricle Caused by Cerebral Atrophy in a Patient with Anterior Thalamic Nucleus DBS. ( 26819942 )
2015
33
Cerebral atrophy in mild cognitive impairment: A systematic review with meta-analysis. ( 27239527 )
2015
34
REMOVED: Cerebral atrophy is linked to clinical severity and worsens with aging in patients with Pelizaeus-Merzbacher disease and Spastic Paraplegia type 2. ( 29887120 )
2015
35
Sturge-Weber syndrome with late onset hemiplegic migraine-like attacks and progressive unilateral cerebral atrophy. ( 24045571 )
2014
36
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy. ( 24515696 )
2014
37
VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2). ( 24577744 )
2014
38
Retraction. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008 Dec;131(Pt 12):3311–34. doi:10.1093/brain/awn288. ( 24860127 )
2014
39
Association of SORL1 gene variants with hippocampal and cerebral atrophy and Alzheimer's disease. ( 24938503 )
2014
40
Cerebral atrophy and dementia in type 2 diabetes mellitus: report of two cases and review of literature. ( 24956625 )
2014
41
Cerebral atrophy and subdural haemorrhage after cerebellar and cerebral infarcts in an 8-month-old child after having been stung by a scorpion. ( 24962491 )
2014
42
Cerebral atrophy in a vitamin B12-deficient infant of a vegetarian mother. ( 25076673 )
2014
43
Subdural hemorrhages associated with antithrombotic therapy in infants with cerebral atrophy. ( 25113301 )
2014
44
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. ( 23303849 )
2013
45
Methylglyoxal, cognitive function and cerebral atrophy in older people. ( 22496536 )
2013
46
Global cerebral atrophy after subarachnoid hemorrhage: a possible marker of acute brain injury and assessment of its impact on outcome. ( 22890637 )
2013
47
Cerebral atrophy in elderly with subjective memory complaints. ( 23239111 )
2013
48
Cerebral atrophy is an independent risk factor for unfavorable outcome after spontaneous supratentorial intracerebral hemorrhage. ( 23412376 )
2013
49
Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage. ( 23662822 )
2013
50
Brain docosahexaenoic acid [DHA] incorporation and blood flow are increased in chronic alcoholics: a positron emission tomography study corrected for cerebral atrophy. ( 24098376 )
2013

Variations for Cerebral Atrophy

ClinVar genetic disease variations for Cerebral Atrophy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MLLT1 NM_005934.3(MLLT1): c.1418G> A (p.Arg473Gln) single nucleotide variant Likely pathogenic rs749203329 GRCh37 Chromosome 19, 6213798: 6213798
2 MLLT1 NM_005934.3(MLLT1): c.1418G> A (p.Arg473Gln) single nucleotide variant Likely pathogenic rs749203329 GRCh38 Chromosome 19, 6213787: 6213787
3 DNMT1 NM_001130823.2(DNMT1): c.2718C> G (p.Phe906Leu) single nucleotide variant Uncertain significance rs1057518774 GRCh38 Chromosome 19, 10148886: 10148886
4 DNMT1 NM_001130823.2(DNMT1): c.2718C> G (p.Phe906Leu) single nucleotide variant Uncertain significance rs1057518774 GRCh37 Chromosome 19, 10259562: 10259562
5 DGUOK NM_080916.2(DGUOK): c.65C> T (p.Pro22Leu) single nucleotide variant Uncertain significance rs757962437 GRCh38 Chromosome 2, 73926975: 73926975
6 DGUOK NM_080916.2(DGUOK): c.65C> T (p.Pro22Leu) single nucleotide variant Uncertain significance rs757962437 GRCh37 Chromosome 2, 74154102: 74154102
7 DGUOK NM_080916.2(DGUOK): c.278G> A (p.Gly93Glu) single nucleotide variant Uncertain significance rs1553403624 GRCh38 Chromosome 2, 73946741: 73946741
8 DGUOK NM_080916.2(DGUOK): c.278G> A (p.Gly93Glu) single nucleotide variant Uncertain significance rs1553403624 GRCh37 Chromosome 2, 74173868: 74173868
9 SETBP1 NM_015559.3(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic rs1555706928 GRCh38 Chromosome 18, 44951954: 44951954
10 SETBP1 NM_015559.3(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic rs1555706928 GRCh37 Chromosome 18, 42531919: 42531919

Expression for Cerebral Atrophy

Search GEO for disease gene expression data for Cerebral Atrophy.

Pathways for Cerebral Atrophy

Pathways related to Cerebral Atrophy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.84 DNAJC3 DNAJC5

GO Terms for Cerebral Atrophy

Sources for Cerebral Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....